Metabolic care, simplified.

Compliance & Disclaimers

• • Membership pricing reflects starting dose tiers; final pricing depends on prescribed dose and titration plan.
• • Treatment is not guaranteed and requires a comprehensive evaluation by an independently licensed clinician. Pricing shown does not include the required medical consultation.
• • Indication: Compounded tirzepatide and retatrutide are prescribed off-label for chronic weight management in adults who meet clinical criteria; they are not approved by the FDA for any indication.
• • Do not use if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), are pregnant or breastfeeding, or have a history of pancreatitis or severe gastrointestinal disease. Disclose all medications, supplements, and conditions.
• • Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, fatigue, and injection-site reactions. Serious risks include pancreatitis, gallbladder disease, kidney injury, and (in animal studies) thyroid C-cell tumors.
• • FDA shortage status: Semaglutide and tirzepatide were removed from the FDA drug-shortage list in 2024. 503A compounding of these molecules is now limited to specific clinical-need exceptions (e.g. documented allergy or a commercially unavailable dose) as determined by the prescribing clinician.
• • Compounded tirzepatide and retatrutide are prepared and dispensed by independently licensed 503A or 503B U.S. pharmacies and are not FDA-approved finished drug products.
• • Geographic availability based on clinician licensure. Medication ships only after clinical approval.

Have questions about candidacy or safety? Talk to a clinician before starting any prescription therapy.